1-7 of 7
Yasumichi Hitoshi
Close
Sort by
Journal Articles

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm

Kotaro Shide, Takuro Kameda, Vadim Markovtsov, Haruko K. Shimoda, Elizabeth Tonkin, Shuling Fang, Chian Liu, Marina Gelman, Wayne Lang, Jason Romero, John McLaughlin, Somasekhar Bhamidipati, Jeffrey Clough, Caroline Low, Andrea Reitsma, Stacey Siu, Polly Pine, Gary Park, Allan Torneros, Matt Duan, Rajinder Singh, Donald G. Payan, Takuya Matsunaga, Yasumichi Hitoshi, Kazuya Shimoda
Journal: Blood
Blood (2011) 117 (25): 6866–6875.
https://doi.org/10.1182/blood-2010-01-262535
Published: 2011
Includes: Supplemental data
Journal Articles

Role of Spleen Tyrosine Kinase Signaling in Early B Cell Acute Lymphoblastic Leukemia.

Tatiana Perova, MSc, Lauryl Nutter, PhD, Irina Matei, PhD, Ildiko Grandal, MSc, Polly Pine, Yasumichi Hitoshi, PhD, Johann K. Hitzler, MD, Cynthia J Guidos, PhD, Jayne S Danska, PhD
Journal: Blood
Blood (2009) 114 (22): 3092.
https://doi.org/10.1182/blood.V114.22.3092.3092
Published: 2009
Journal Articles

Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2 V617F-Induced Murine MPD Model.

Kotaro Shide, Takuro Kameda, Vadim Markovtsov, Takuya Matsunaga, Haruko Shimoda, Tomonori Hidaka, Keiko Katayose, Yoko Kubuki, Somasekhar Bhamidipati, Gary Park, Allan Torneros, Matt Duan, Yasumichi Hitoshi, Kazuya Shimoda
Journal: Blood
Blood (2009) 114 (22): 3897.
https://doi.org/10.1182/blood.V114.22.3897.3897
Published: 2009
Journal Articles

In Vitro and in Vivo Inhibition of JAK2 Signaling by Potent and Selective JAK2 Inhibitor

Vadim Markovtsov, Elizabeth Tonkin, Shuling Fang, Chiang Liu, Marina Gelman, Wayne Lang, Jason Romero, John McLaughlin, Somasekhar Bhamidipati, Jeffrey Clough, Rajinder Singh, Caroline Low, Andrea Reitsma, Vanessa Taylor, Stacey Siu, Gary Park, David Sweeney, Polly Pine, Allan Torneros, George Clemens, Matt Duan, Ruby Daniel, Donald Payan, MD, Sacha Holland, Yasumichi Hitoshi, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 3721.
https://doi.org/10.1182/blood.V112.11.3721.3721
Published: 2008
Journal Articles

Targeting Myeloproliferative Diseases with JAK2 Inhibitors.

Vadim Markovtsov, PhD, Diane Yu, Marina Gelman, PhD, Wayne Lang, Vanessa C. Taylor, PhD, Stacey Huynh, Roy Frances, Shuling Fang, John McLaughlin, Sohasekhar Bhamidipati, PhD, Jeffrey Clough, PhD, Rajinder Singh, PhD, Gary Park, PhD, David Sweeney, PhD, Elizabeth Tonkin, PhD, Rena Bahjat, PhD, Betty Chang, PhD, Polly Pine, PhD, Ruby Daniel, PhD, Donald G. Payan, PhD, Sacha Holland, PhD, Yasumichi Hitoshi, PhD
Journal: Blood
Blood (2007) 110 (11): 3550.
https://doi.org/10.1182/blood.V110.11.3550.3550
Published: 2007
Journal Articles

Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target.

Linfeng Chen, PhD, Przemyslaw Juszczynski, M.D., Ph.D., Yasumichi Hitoshi, Ph.D., Wen Chen, M.D., Jeffery L. Kutok, M.D., Margaret A. Shipp, M.D.
Journal: Blood
Blood (2006) 108 (11): 226.
https://doi.org/10.1182/blood.V108.11.226.226
Published: 2006
Journal Articles

An Orally Bioavailable Inhibitor of FLT3 and Syk Kinases Prevents Tumor Growth in Subcutaneously Implanted Human Tumor Xenografts and Promotes Cell Death of FLT3 Mutant AML Cells.

Polly R. Pine, PhD, Rena Bahjat, PhD, Betty Chang, PhD, Vanessa Taylor, Ph.D, Vadim Markovstov, Ph.D, Yasumichi Hitoshi, MD, PhD, Elliott Grossbard, MD
Journal: Blood
Blood (2005) 106 (11): 243.
https://doi.org/10.1182/blood.V106.11.243.243
Published: 2005